₨ 90,000
Uses
Kadcyla is indicated for the treatment of:
- Metastatic breast cancer (MBC): HER2-positive breast cancer that has spread to other parts of the body after prior treatment with trastuzumab and a taxane.
- Early breast cancer (EBC): HER2-positive early breast cancer when there is residual invasive disease after neoadjuvant (before surgery) treatment with a taxane and trastuzumab.
Dosage and Administration
Kadcyla is administered as an intravenous infusion, typically once every three weeks. The first infusion usually takes 90 minutes, and subsequent infusions may be administered over 30 minutes if the first infusion is well-tolerated.Common Side Effects
Some of the most common side effects reported in people taking Kadcyla include:
- Fatigue and weakness.
- Nausea and constipation.
- Headaches and muscle or joint pain.
- Low platelet count (thrombocytopenia), which can lead to easy bruising or bleeding.
- Peripheral neuropathy, which is numbness or tingling in the hands and feet.
Important Safety Information
Kadcyla has serious warnings, including a boxed warning from the FDA, about the risks of severe heart problems, liver problems, and potential fetal harm. It is not recommended for use during pregnancy, and women of childbearing age should use effective contraception during treatment and for at least seven months after the last dose.Disclaimer: This information is for general knowledge and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read.
₨ 10,000
